Abstract-Stress hyperglycemia and acute graft-versus-host disease (GVHD), the major early complication of hematopoietic stem cell transplantation (HSCT), are both associated with excessive release of inflammatory cytokines. We investigated whether new-onset hyperglycemia immediately after HSCT predicts acute GVHD. We studied nondiabetic adult recipients of human leukocyte antigen-matched HSCT (peripheral blood stem cells) for acute leukemia. Using mean morning serum glucose on Days 1-10, we classified hyperglycemia as: mild (6.11-8.33 mmol/L), moderate (8.34-9.98), and severe (minimum of 9.99). Subjects who were GVHD-free on Day 10 were followed during Days 11-100 for grades II-IV acute GVHD or competing event. Evaluation utilized cumulative incidence-based proportional hazards regression. Subjects (n=328) were age 18-74, median of 49 years. Per body mass index (BMI)-25.0 % were obese (BMI, 30-48), 33.8 % overweight (25 to <30), 30.8 % normal weight (21 to <25), and 10.4 % lean (18 to <21). Mild, moderate, or severe hyperglycemia occurred during Days 1-10 in 50.0, 21.3, and 16.8 % of subjects, respectively. Cumulative incidence on Day 100 was 44.8 (±2.8)% acute GVHD and 7.9 (±-1.5)% competing event. Among normal-to-overweight subjects (n=212), severe hyperglycemia developed in 14.2 % (n=30) and more than doubled the risk of acute GVHD (hazards ratio, 2.71; 95 % CI, 1.58-4.65-adjusted for donor/recipient characteristics, prophylactic regimen, and mucositis). In contrast, among obese subjects (n=82), severe hyperglycemia developed in 30.5 % (n= 25) but did not significantly affect risk of GVHD. (No lean subjects (n=34) developed severe hyperglycemia.) Hyperglycemia that was less than severe had an effect indistinguishable from normoglycemia. In nondiabetic patients, severe hyperglycemia immediately after allogeneic HSCT indicates increased likelihood of acute GVHD. This association is absent in obese patients, who may be primed by obesity-induced inflammation to develop severe hyperglycemia even without experiencing the cytokine storm that is essential to GVHD pathogenesis.
morphisms) and graft characteristics (source of stem cells, cytomegalovirus (CMV) serostatus of donor and recipient, human leukocyte antigen (HLA) and minor histocompatibility antigen mismatch, and conditioning regimen) [1] [2] [3] [4] [5] [6] [7] . A long-established clinical risk factor, female-to-male graft, may no longer be reliably associated with acute GVHD [2] .
Biological predictors of acute GVHD are needed, and several candidates have been identified. Systemic elevation of inflammatory cytokines immediately before and after HSCT is crucial to the pathogenesis of acute GVHD. A composite biomarker panel of four proteins (interleukin (IL)-2-receptor-α, tumor necrosis factor (TNF)-receptor-1, IL-8, and hepatocyte growth factor) correlates with the clinical diagnosis of acute GVHD [8] , and IL-2, TNF-α, and Fas have each been observed to rise prior to symptomatic acute GVHD [9] [10] [11] [12] . However, assessment of these potential biomarkers is expensive and not routinely available.
Like acute GVHD, stress hyperglycemia in critically ill patients is closely associated with systemic elevation of inflammatory cytokines, including IL-6 and TNF-α, and is predictive of poor clinical outcome [13] [14] [15] [16] . Unlike inflammatory cytokines, however, serum glucose is routinely monitored in the days after allogeneic HSCT, making hyperglycemia practical to consider as a potential biomarker for acute GVHD. In fact, a preliminary association was recently reported between acute GVHD grades II-IV and level of hyperglycemia during the neutropenic period [17] .
However, it was unclear from the previous study [17] whether the occurrence of hyperglycemia preceded or merely coincided with acute GVHD, because acute GVHD may occur before as well as after neutrophil engraftment [18] . Moreover, the need to monitor patients throughout the variable neutropenic period would delay the calculation of mean morning serum glucose (MSG) until engraftment is confirmed, and such delay could diminish the ability to predict acute GVHD well before the onset of symptoms. Therefore, we investigated whether monitoring MSG for the 10 days immediately after HSCT would be sufficient to predict development of acute GVHD during the subsequent 90 days, independently of other risk factors. To ensure that hyperglycemia following HSCT was of new onset and hence potentially related to incipient acute GVHD, we excluded patients with preexisting diabetes mellitus or recent hyperglycemia from our study.
METHODS
Eligibility. Subjects were consecutive patients, age 18 years or older, who underwent primary, HLAmatched, allogeneic HSCT for acute myeloid leukemia, myelodysplastic syndrome, or acute lymphoid leukemia at our institution between October 2003 and April 2009. Further eligibility criteria were: graft of peripheral blood stem cells; GVHD prophylaxis that included tacrolimus with sirolimus and/or methotrexate (MTX) or a combination of cyclosporine with MTX and/or mycophenolate mofetil; and status alive and free of GVHD on Day 10 after allogeneic HSCT, when follow-up began. Patients were excluded if their conditioning regimen included rabbit antithymoglobulin; if they had a history of diabetes mellitus, MSG of >5.55 mmol/L, or random serum glucose of >7.77 mmol/L prior to conditioning; or recent corticosteroid use prior to admission for HSCT, other than the single dose of corticosteroids routinely administered on the day of transplantation.
Study Conduct. This study was approved in advance by the hospital's institutional review board, which provided a waiver of informed consent to ensure that all eligible patients, including those lost to follow-up, would be included in the study cohort. Data were obtained from electronic medical and pharmacy records, the cancer registry, clinical trial adverse events records, and a database of standard HSCT outcomes (i.e., acute GVHD, leukemic relapse, and death without relapse) maintained for a federally mandated registry.
Acute GVHD. Using established criteria for GVHD [19] , transplant physicians assessed patients daily during the hospitalization for HSCT and twice weekly thereafter through the study's close on Day 100. For the study, acute GVHD was defined as cases that began during Days 11-100 after allogeneic HSCT and reached at least grade II. The competing event for acute GVHD during Days 11-100 was treatment failure (leukemic relapse or nonrelapse mortality) without prior acute GVHD.
Risk Factors for Acute GVHD. The study's primary risk factor, level of hyperglycemia, was derived from the mean of MSG values on Days 1-10. When present, hyperglycemia was categorized as mild (6.11-8.33 mmol/L), moderate (8.34-9 .98 mmol/L), or severe (minimum of 9.99 mmol/L). Serum glucose was measured between midnight and 0800 hours daily as part of the routine chemistry panel. Covariates considered in the analysis included characteristics of donor, recipient, or graft: type of donor (unrelated versus sibling); sex of donor and recipient (specifically, fe-male-to-male and female-to-female versus other graft); CMV serostatus of donor and recipient (specifically, seronegative-to-seronegative graft [2] versus other graft); underlying diagnosis (myeloid versus lymphoid); stage of disease (early (first complete response or refractory anemia), intermediate (second or third complete response or first relapse), or late (all other stages)); conditioning (myeloablative total body irradiation (TBI) based [6] versus other); regimen for GVHD prophylaxis; selfreported ethnicity; age; and Karnofsky score at HSCT.
Additional covariates were body mass index (BMI) at admission and mucositis. BMI was categorized as obese (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) , overweight (25 to <30), normal weight (21 to <25), and lean (18 to <21). Had we instead defined lean as BMI of 18 to <20, as is typically done, there would have been half as many lean subjects, with too little power to detect that group's marked association with acute GVHD, and the normal weight group would then have included several lean subjects not at risk of severe hyperglycemia (observed only among subjects of BMI of 21 or more). The maximum degree of mucositis (observed from start of conditioning through Day 10) was assessed separately by clinical examination and by functional/symptomatic score, each graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 [20] . Mucositis was not recorded for subjects who were not participating in a clinical trial; however, such subjects were retained in all current analyses by handling "unscored for mucositis" as a separate risk category. Further covariates from Days 1 to 10 included: fever (>38.1°C) attributed to infection, whether suspected or confirmed; corticosteroid use; days of insulin use; and days of total parenteral nutrition (TPN), given as needed using the Harris-Benedict formula [21] , 25-30 kcalkg
Proportions were compared using Chi-square tests, and means were compared using t tests. Determinants of MSG during Days 1-10 were identified using a generalized linear mixed model, for which glucose values were log-transformed to normalize their skewed distribution. To estimate the occasional missing MSG value, the model shown in Table 3 was expanded to include use of insulin on the current day and on previous days.
The primary association under study, between level of hyperglycemia and cumulative incidence of acute GVHD, was investigated in univariate analysis using the Gray test [22] and in multivariate analysis using cumulative incidence-based proportional hazards regression [23, 24] . Covariates and interactions were retained if they improved the model's fit to the observed data.
RESULTS
Sample. Subjects (n=328, HSCT hematopoietic stem cell transplantation, TBI total body irradiation, BuCy busulfan+cyclophosphamide, Tacro tacrolimus, Siro sirolimus, MTX methotrexate insulin was administered during the 10 days, the initial dose was a median of 10 (5th to 95th percentile range, 4-20) units and the last dose was a median of 20 (5-70) units. Most subjects developed fever attributed to infection, but very few patients received corticosteroids. By Day 10, nearly all (88.1 %) subjects had developed some degree of hyperglycemia, and one in six subjects had developed severe hyperglycemia ( Table 2) .
Determinants of Morning Serum Glucose during Days 1-
10. In four (1.2 %) subjects, one of the ten daily measurements of MSG was missing at random and was estimated (as described in "METHODS") to permit calculation of a 10-day mean glucose for each subject. As shown in Table 3 , during the 10 days following HSCT, MSG level was increased on Day 1 (when a single dose of glucocorticoid was routinely administered) and was further elevated by increasing category of BMI; by current use of TPN and by each prior day of TPN use within the 10-day period; by male recipient, tacrolimus-based prophylaxis, or both; by the combination of Hispanic recipient with unrelated donor (but not by ethnicity or unrelated donor alone); and by myeloablative TBI-based conditioning.
Other characteristics (recipient's age, underlying diagnosis, CMV serostatus of donor and recipient, mucositis by either scoring system, fever attributed to infection, and nonroutine corticosteroid use during Days 1-10) were unassociated with MSG. Same-day use of insulin, being a result rather than a cause of hyperglycemia, would not have been valid to consider as a determinant of MSG.
Acute GVHD Grades II-IV During Days 11-100. Among the cases of acute GVHD (n=147), 61.9 % had grade II disease; distribution of grade did not differ by presence of severe hyperglycemia. At Day 100 posttransplantation, the cumulative incidence of acute GVHD was 44.8 (±2.8)%. Another 7.9 (±1.5)% of subjects developed a competing event (leukemic relapse (n=19) and nonrelapse mortality (n=7)) by Day 100.
In univariate analysis of the entire sample (Fig. 1a) , cumulative incidence of acute GVHD was higher after severe hyperglycemia than after the other three glycemic categories combined (58.2 (±6.8) versus 42.1 (±3.0)%, p= 0.03). However, this association between GVHD and severe hyperglycemia varied by category of BMI: among normal-to-overweight subjects, severe hyperglycemia developed in 14.2 % and was markedly associated with acute GVHD (73.3 (±8.4) versus 41.2 (±3.7)%, p<0.001; Fig. 1b) . In contrast, among obese subjects, severe hyperglycemia developed in 30.5 % and was not associated with acute GVHD (Fig. 1c) . Severe hyperglycemia did not develop among lean subjects (n=34), who had a relatively low cumulative incidence of acute GVHD (26.5 (±7.7)%) and a relatively high incidence of competing events (17.6 (±6.7)%, five relapse and one nonrelapse death without prior GVHD; data not shown).
These univariate findings were strengthened when established risk factors for GVHD (sirolimus-based prophylactic regimen, sex and CMV serostatus of donor and recipient, mucositis, and underlying diagnosis) were taken into account. As shown in Table 4 , severe hyperglycemia more than doubled the risk of GVHD among normal-to-overweight subjects but did not significantly affect risk among obese subjects. Lean BMI remained associated with reduced likelihood of acute GVHD (Table 4) .
Covariates excluded from the final model for lack of effect on fit were: age, ethnicity, unrelated versus sibling donor, stage of disease, Karnofsky score, and Days 1-10 factors (fever attributed to infection, corticosteroid use, days of TPN, and days of insulin). Because HSCT hematopoietic stem cell transplantation the two mucositis scores were highly correlated, the final model retained only the more significant one, clinical examination score. Subjects not scored for mucositis due to nonparticipation in a clinical trial had a risk of acute GVHD that fell between those of subjects with and without mucositis, as would be expected from a mixture of these two risk groups.
DISCUSSION
In contrast to a previous report [17] that associated acute GVHD with moderate-to-severe hyperglycemia prior to neutrophil engraftment, the current study has narrowed the GVHD-associated signal to severe hyperglycemia evident during the first 10 days after allogeneic HSCT. We found that while lesser degrees of hyperglycemia are unassociated with acute GVHD, severe hyperglycemia immediately after transplantation indicates an increased likelihood of developing this complication. Among patients who are obese, however, severe hyperglycemia has no prognostic value, for reasons explored below. Finally, level of blood glucose does not correlate with grade of acute GVHD: the severity distribution of GVHD was alike in current subjects who did and did not experience severe hyperglycemia. The latter finding suggests that the pathogenesis of GVHD is the same regardless of its severity and that the ultimate grade of GVHD may be determined by a different set of factors than those that initiate the disease.
That severe hyperglycemia after transplantation is predictive of acute GVHD in nonobese subjects but not in obese patients may result from the chronic inflammation triggered by obesity [25] . In brief, overnutrition results in recruitment of monocytes into the enlarging adipose tissue. There, the cells differentiate into classically activated macrophages that encircle necrotic adipocytes and produce pro-inflammatory molecules such as TNF and IL-1β. Crosstalk between the classically activated macrophages in obese adipose tissue and pathogenic CD4+ and CD8+ T cells further amplifies the inflammatory milieu. The inflammation associated with obesity exceeds the control of anti-inflammatory mechanisms resident in alternatively activated macrophages, found mainly in lean adipose tissue. The result of this chronic inflammation is insulin resistance, in which impaired glucose disposal leads to hyperinsulinemia, hyperglycemia, and hyperlipidemia [25] .
Thus, primed by obesity-induced chronic inflammation, obese subjects might develop severe hyperglycemia as a consequence of HSCT-related stress alone, even without the inflammatory cytokine storm associated with GVHD pathogenesis. In contrast, nonobese HSCT recipients may be unlikely to develop severe hyperglycemia without also experiencing cytokine storm. To learn whether correlation between severe hyperglycemia and excessive cytokine levels differs between obese and nonobese HSCT recipients, future studies should track glucose in tandem with inflammatory cytokines during pretransplantation conditioning HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease, TBI total body irradiation, TPN total parenteral nutrition, BMI body mass index a Categories of body mass index-lean (18 to <21), normal (21 to <25), overweight (25 to <30), and obese (30-48) Fig. 1 . Cumulative incidence of acute GVHD and competing events, by glycemic category after allogeneic HSCT. a In all subjects (N=328). b In normal-to-overweight subjects (N=212). c In obese subjects (N=82). This landmark analysis follows subjects during Days 11-100 after HSCT. Unbroken lines represent cumulative incidence of acute GVHD, and dotted lines represent cumulative incidence of treatment failure without prior acute GVHD. and the first 10 days after HSCT, analyzing the data with attention to category of BMI. Whether tighter control of serum glucose before and after allogeneic HSCT might reduce the incidence of acute GVHD, particularly among normal-to-overweight recipients, awaits a clinical trial. Previously, a pilot trial of intensive glucose management after allogeneic HSCT did not detect a reduced incidence of acute GVHD [26] . However, that small, nonrandomized trial must be regarded as inconclusive, especially because its eligibility criteria did not target normal-to-overweight subjects at high risk of severe hyperglycemia, the patient group our study suggests would be most likely to benefit from the intervention.
Our study also observed that the leanest patients do not develop severe hyperglycemia following allogeneic HSCT and that acute GVHD develops less often in lean patients, apparently preempted by competing events, chiefly leukemic relapse. Recently, underweight (BMI, <18), a degree of leanness not found in the current study, was associated with lower risk of acute GVHD among recipients of allogeneic HSCT but only among subjects with a related donor [27] . In our study, however, the type of donor had no effect on the association between BMI and acute GVHD. Elsewhere, a potential association has been reported between increasing category of BMI and risk of acute GVHD [28] . In contrast, our study detected no greater risk in obese or overweight subjects than in normal weight subjects.
To better understand hyperglycemia following allogeneic HSCT, we identified factors independently associated with increase in blood glucose during the first 10 days after allogeneic HSCT. Two of these risk factors (male gender and the combination of Hispanic ethnicity with unrelated donor) are novel, while the other risk factors for hyperglycemia are well established, includ- GVHD graft-versus-host disease, CMV cytomegalovirus, ALL acute lymphoid leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome, NS not statistically significant (p>0.50) *Covariates were not evaluated for statistical significance; they were included in the model solely to control potential confounding of the primary association a interaction between glycemic category and body mass was statistically significant, p=0.004 ing: greater BMI, which promotes insulin resistance [25] ; tacrolimus [29] , which impairs insulin secretion [30] ; glucocorticoids (administered on Day 1), which cause impaired glucose uptake, enhanced gluconeogenesis, and increased glycogenolysis [31] ; myeloablative conditioning with total body irradiation, which like chemotherapy, may damage islet beta cells directly [32, 33] ; and TPN, which is associated with profound hyperglycemia even when used per clinical guidelines in HSCT recipients [34] . From Table 3 , it is clear that a patient would have needed nearly all of these risk factors to develop severe hyperglycemia, which corresponds to nearly double (190 %) the MSG level estimated for a patient with none of the factors. Although conceived and executed after all subjects had completed their first 100 days of care, our study was nevertheless free of the recall and selection biases common to retrospective studies, because we were able to study 100 % of eligible patients and because our data had been recorded as measurements were made and as events occurred, i.e., prospectively. The fact that clinicians were unaware of hyperglycemia as a potential predictive factor at the time they were monitoring or prophylaxing subjects for acute GVHD was a strength of the study, because it ensured against diagnostic bias.
A limitation of the study was that only routinely recorded data were available for study. Thus, we had access to data on MSG but not on cytokines such as IL-6, IL-18, and TNF-α, which have been shown to rise after induction of hyperglycemia [16] . Specimens for MSG testing were collected in the early morning hours when fasting was presumed but not formally documented. Data on one of the covariates, mucositis [3] , had been recorded only for subjects who were clinical trial participants. Nonetheless, we were able to include subjects who lacked mucositis evaluations in all current analyses, detecting increased risk of acute GVHD in subjects found to have ulcerations on clinical examination, whether or not symptoms interfered with oral intake. This finding is consistent with a previous report [3] that painful mucositis requiring TPN or opiate analgesics precedes acute GVHD, although direct comparison between our finding and the previous one is precluded by noncomparable grading of mucositis.
Another limitation of our study is that data were unavailable on diarrhea related to conditioning, a GVHD risk factor independent of mucositis [4, 5] . In addition, our study was uninformative about hyperacute GVHD, because our eligibility criteria excluded from the cohort those patients who developed GVHD before Day 11 after allogeneic HSCT. Finally, because the majority of GVHD cases were grade II, there were not sufficient numbers of grades III-IV cases to support analyzing these separately.
In conclusion, severe hyperglycemia in the first 10 days after allogeneic HSCT is a novel predictor of acute GVHD among nonobese patients. This prognostic signal is detectable well before onset of symptoms, is independent of established risk factors for GVHD, and requires only short-term monitoring of a marker (glucose) that is routinely measured in clinical practice.
